VNIM
CRL icon

Vaughan Nelson Investment Management’s Charles River Laboratories CRL Stock Holding History

Vaughan Nelson Investment Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-159
Closed -$66K – 220
2021
Q3 		$66K Buy
+159
New +$66K ﹤0.01% 231

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vaughan Nelson Investment Management's CRL Position: Q4 2021 in Review

Vaughan Nelson Investment Management sold out of Charles River Laboratories (CRL) in Q4 2021, closing a stake of 159 shares — an estimated $66K sold.

Vaughan Nelson Investment Management first reported a position in CRL in Q3 2021 and held it in 1 quarter. The position peaked at $66K in Q3 2021. 707 funds tracked by Wall St. Rank hold CRL as of Q4 2021.

  • Vaughan Nelson Investment Management reported no remaining Charles River Laboratories position as of Q4 2021 after selling out during the quarter.
  • Vaughan Nelson Investment Management sold 159 Charles River Laboratories shares in Q4 2021, an estimated $66K.
  • Vaughan Nelson Investment Management first reported a position in Charles River Laboratories in Q3 2021 and held it in 1 quarter.
  • Vaughan Nelson Investment Management's Charles River Laboratories position peaked at $66K in Q3 2021.
  • 707 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2021.

Based on Vaughan Nelson Investment Management's 13F filing for Q4 2021, filed 13 Jan 2022.